United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 1 mg in 1 g - triamcinolone acetonide dental paste usp, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. triamcinolone acetonide dental paste usp, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat. pediatric use the safety and efficacy of triamcinolone acetonide dental paste usp, 0.1% in children is unknown. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere

United States - English - NLM (National Library of Medicine)

rebel distributors corp - triamcinolone acetonide (unii: f446c597ka) (triamcinolone - unii:1zk20vi6ty) - triamcinolone acetonide 1 mg in 1 g - triamcinolone acetonide dental paste usp, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. triamcinolone acetonide dental paste usp, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat. pediatric use the safety and efficacy of triamcinolone acetonide dental paste usp, 0.1% in children is unknown. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere

United States - English - NLM (National Library of Medicine)

avkare - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 1 mg in 1 g - triamcinolone acetonide dental paste usp, 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. triamcinolone acetonide dental paste usp, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat. pediatric use the safety and efficacy of triamcinolone acetonide dental paste usp, 0.1% in children is unknown. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. administration of corticosteroid-containing dental pastes to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 1 mg in 1 g - triamcinolone acetonide dental paste, usp 0.1% is indicated for adjunctive treatment and for the temporary relief of symptoms associated with oral inflammatory lesions and ulcerative lesions resulting from trauma. triamcinolone acetonide dental paste is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation; it is also contraindicated in the presence of fungal, viral, or bacterial infections of the mouth or throat.

United States - English - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 5 mg in 1 g - triamcinolone acetonide ointment, usp 0.5% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations. pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hpa axis suppression and cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. hpa axis suppression, cushing’s syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to acth stimulation. manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. administration of topical corticosteroids to children should be li

United States - English - NLM (National Library of Medicine)

teligent pharma, inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 1 mg in 1 g - triamcinolone acetonide cream 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - triamcinolone (unii: 1zk20vi6ty) (triamcinolone - unii:1zk20vi6ty) - triamcinolone 0.25 mg - triamcinolone acetonide cream usp is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. triamcinolone acetonide cream usp is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

United States - English - NLM (National Library of Medicine)

sandoz inc - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 40 mg in 1 ml - where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension, usp is indicated for intramuscular use as follows: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. to tide the patient over a critical period of the disease in

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - triamcinolone acetonide 40 mg in 1 ml - intramuscular where oral therapy is not feasible, injectable corticosteroid therapy, including triamcinolone acetonide injectable suspension is indicated for intramuscular use as follows: allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases: bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. gastrointestinal diseases: to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. hematologic disorders: acquired (autoimmune) hemolytic anemia, diamond-blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. miscellaneous: trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. neoplastic diseases: for the palliative management of leukemias and lymphomas. nervous system: acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. ophthalmic diseases: sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. renal diseases: to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. respiratory diseases: berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis and systemic lupus erythematosus. intra-articular the intra-articular or soft tissue administration of triamcinolone acetonide injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. triamcinolone acetonide injectable suspension is contraindicated in patients who are hypersensitive to any components of this product (see warnings: general ). intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.

United States - English - NLM (National Library of Medicine)

dechra veterinary products - nystatin (unii: bdf1o1c72e) (nystatin - unii:bdf1o1c72e), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), thiostrepton (unii: hr4s203y18) (thiostrepton - unii:hr4s203y18), triamcinolone acetonide (unii: f446c597ka) (triamcinolone acetonide - unii:f446c597ka) - animax cream combines nystatin, neomycin sulfate, thiostrepton and triamcinolone acetonide. each gram contains: nystatin................................................................................................................ 100,000 units neomycin sulfate equivalent to neomycin base................................................................ 2.5 mg thiostrepton ............................................................................................................. 2,500 units triamcinolone acetonide ................................................................................................... 1 mg in an aqueous non-irritating vanishing cream base of polyoxyethylene fatty alcohol ether, sorbitol solution, propylene glycol, white petrolatum, polyoxyl 40 stearate, glyceryl monostearate, titanium dioxide, citric acid, ethylenediamine, methylparaben, propylparaben.